These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 24700697)
21. Resistance of hepatitis C virus to NS3-4A protease inhibitors: mechanisms of drug resistance induced by R155Q, A156T, D168A and D168V mutations. Courcambeck J; Bouzidi M; Perbost R; Jouirou B; Amrani N; Cacoub P; Pèpe G; Sabatier JM; Halfon P Antivir Ther; 2006; 11(7):847-55. PubMed ID: 17302247 [TBL] [Abstract][Full Text] [Related]
22. P4 cap modified tetrapeptidyl alpha-ketoamides as potent HCV NS3 protease inhibitors. Sun DX; Liu L; Heinz B; Kolykhalov A; Lamar J; Johnson RB; Wang QM; Yip Y; Chen SH Bioorg Med Chem Lett; 2004 Aug; 14(16):4333-8. PubMed ID: 15261297 [TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo isotope effects with hepatitis C protease inhibitors: enhanced plasma exposure of deuterated telaprevir versus telaprevir in rats. Maltais F; Jung YC; Chen M; Tanoury J; Perni RB; Mani N; Laitinen L; Huang H; Liao S; Gao H; Tsao H; Block E; Ma C; Shawgo RS; Town C; Brummel CL; Howe D; Pazhanisamy S; Raybuck S; Namchuk M; Bennani YL J Med Chem; 2009 Dec; 52(24):7993-8001. PubMed ID: 19894743 [TBL] [Abstract][Full Text] [Related]
24. Synthesis of empagliflozin, a novel and selective sodium-glucose co-transporter-2 inhibitor, labeled with carbon-14 and carbon-13. Hrapchak M; Latli B; Wang XJ; Lee H; Campbell S; Song JJ; Senanayake CH J Labelled Comp Radiopharm; 2014 Oct; 57(12):687-94. PubMed ID: 25332189 [TBL] [Abstract][Full Text] [Related]
25. Potent triazolyl-proline-based inhibitors of HCV NS3 protease. Naud J; Lemke C; Goudreau N; Beaulieu E; White PD; Llinàs-Brunet M; Forgione P Bioorg Med Chem Lett; 2008 Jun; 18(11):3400-4. PubMed ID: 18448339 [TBL] [Abstract][Full Text] [Related]
26. Synthesis of stable isotope labeled anacetrapib, its major metabolites and [(14) C]anacetrapib. Kuethe JT; Soli ED; Royster P; Quinn CA J Labelled Comp Radiopharm; 2013 Oct; 56(12):600-8. PubMed ID: 24285236 [TBL] [Abstract][Full Text] [Related]
27. Buscopan labeled with carbon-14 and deuterium. Latli B; Stiasni M; Hrapchak M; Li Z; Grinberg N; Lee H; Busacca CA; Senanayake CH J Labelled Comp Radiopharm; 2016 Nov; 59(13):557-564. PubMed ID: 27753138 [TBL] [Abstract][Full Text] [Related]
28. Synthesis of carbon-14 and stable isotope labeled Avagacestat: a novel gamma secretase inhibitor for the treatment of Alzheimer's disease. Burrell RC; Easter JA; Cassidy MP; Gillman KW; Olson RE; Bonacorsi SJ J Labelled Comp Radiopharm; 2014 Aug; 57(10):600-5. PubMed ID: 25196195 [TBL] [Abstract][Full Text] [Related]
29. [Clarifying the crystal structure of hepatitis C virus NS3/NS4A protease complex--basics for the development of specific HCV protease inhibitors?]. Günther R; Schmidt WE Z Gastroenterol; 1997 Dec; 35(12):1119-21. PubMed ID: 9487645 [No Abstract] [Full Text] [Related]
30. Discovery of achiral inhibitors of the hepatitis C virus NS3 protease based on 2(1H)-pyrazinones. Ortqvist P; Gising J; Ehrenberg AE; Vema A; Borg A; Karlén A; Larhed M; Danielson UH; Sandström A Bioorg Med Chem; 2010 Sep; 18(17):6512-25. PubMed ID: 20673728 [TBL] [Abstract][Full Text] [Related]
31. Synthesis and optimization of a novel series of HCV NS3 protease inhibitors: 4-arylproline analogs. Bilodeau F; Bailey MD; Bhardwaj PK; Bordeleau J; Forgione P; Garneau M; Ghiro E; Gorys V; Halmos T; Jolicoeur ES; Leblanc M; Lemke CT; Naud J; O'Meara J; White PW; Llinàs-Brunet M Bioorg Med Chem Lett; 2013 Jul; 23(14):4267-71. PubMed ID: 23735741 [TBL] [Abstract][Full Text] [Related]
32. Synthesis of BILN 2061, an HCV NS3 protease inhibitor with proven antiviral effect in humans. Faucher AM; Bailey MD; Beaulieu PL; Brochu C; Duceppe JS; Ferland JM; Ghiro E; Gorys V; Halmos T; Kawai SH; Poirier M; Simoneau B; Tsantrizos YS; Llinàs-Brunet M Org Lett; 2004 Aug; 6(17):2901-4. PubMed ID: 15330643 [TBL] [Abstract][Full Text] [Related]